Group 1 - The core viewpoint of the news is that Panlong Pharmaceutical experienced a stock price increase of 5.06%, reaching 32.79 CNY per share, with a total market capitalization of 3.485 billion CNY [1] - Panlong Pharmaceutical, established on September 22, 1997, is located in Xi'an, Shaanxi Province, and was listed on November 16, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition of Panlong Pharmaceutical includes 55.50% from self-produced traditional Chinese medicine, 22.42% from pharmaceutical distribution, 21.42% from traditional Chinese medicine pieces, and 0.52% from other sources [1] Group 2 - Among the top circulating shareholders of Panlong Pharmaceutical, a fund under Huatai PineBridge has reduced its holdings by 36,500 shares, now holding 342,500 shares, which accounts for 0.46% of the circulating shares [2] - The Huatai Zhongzheng Traditional Chinese Medicine ETF (560080) was established on September 26, 2022, with a current scale of 1.814 billion CNY. It has achieved a return of 1.14% this year, ranking 4129 out of 4222 in its category [2] - The fund has a one-year return of 20.45%, ranking 3665 out of 3804, and a cumulative return of 10.4% since its inception [2]

Core Points - On September 15, the company announced that it held a staff representative meeting on September 12, 2025, where Zhu Wenfeng was democratically elected as the employee representative director of the fifth board of directors [2]

陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会任期即 将届满，根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等规范 性文件及《公司章程》的有关规定，为保证董事会的正常运行，公司于 2025 年 9 月 12 日在公司会议室召开职工代表大会，经与会职工代表民主选举，同意朱 文锋先生为公司第五届董事会职工代表董事，朱文锋先生的简历详见附件。 朱文锋先生符合相关法律法规、有关董事任职的资格和条件，将与 2025 年 第二次临时股东会选举产生的非独立董事和独立董事共同组成公司第五届董事 会，任期自本次职工代表大会审议通过之日起至第五届董事会任期届满之日止。 本次选举职工代表董事工作完成后，公司董事会中兼任高级管理人员以及由职工 代表担任的董事人数，总计未超过公司董事总数的二分之一。 关于选举第五届董事会职工代表董事的公告 特此公告。 陕西盘龙药业集团股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002864 证券简称：盘龙药业 公告编号： ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-043 陕西盘龙药业集团股份有限公司 关于董事会完成换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 非独立董事：谢晓林先生、谢晓锋先生、张德柱先生、吴杰先生、黄继林先 生、朱文锋先生（职工代表董事）； 公司第五届董事会成员均具备担任上市公司董事的任职资格，任期自公司 2025 年第二次临时股东会审议通过之日起三年。董事会中兼任公司高级管理人 员以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合 《中华人民共和国公司法》和《公司章程》的有关规定。独立董事的任职资格和 独立性已经深圳证券交易所备案审核无异议。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日召开了职工代表大会，选举产生了 1 名职工代表董事，并于 2025 年 9 月 15 召开了 2025 年第二次临时股东会，选举产生了 5 名非独立董事和 3 名独立董事， 共同组成了公司第五届董事会。现将具体情况公告如下： 一、公司第五届董事会组成情况 公司第五届董事会成员为 9 ...

北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2025 年第二次临时股东会 之 法律意见书 二零二五年九月 0 地 址：北京市东城区银河 SOHO B 座 1509-1510 室 电 话：010-58116099 传 真：010-58116099 Email：Recher@bjrecher.com 北京瑞强律师事务所 2025 年第二次临时股东会 之 法律意见书 北京瑞强律师事务所（以下简称"本所"）接受陕西盘龙药业集团股份有限 公司（以下简称"公司"）的委托，指派本所陈晓昀律师、王志恒律师出席公司 于 2025 年 9 月 15 日下午 14:00 在陕西省西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开的 2025 年第二次临时股东会 （以下简称"本次股东会"）。现依据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券 交易所上市公司股东会网络投票实施细则》（以下简称"《网络投票细则》"） 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、 其他规范性文件及《陕西盘龙药业集团股份 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002864 证券简称：盘龙药业 公告编号：2025-042 陕西盘龙药业集团股份有限公司 关于 2025 年第二次临时股东会决议公告 1.本次股东会未出现否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况： （一）会议召开时间： 1.现场会议召开日期：2025 年 9 月 15 日（星期一）下午 14:00。 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 15 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 15 日 9:15—15:00 期间的任意时间。 （二）现场会议召开地点：西安市灞桥区现代纺织产业园灞柳二路2801号陕 西盘龙医药股份有限公司二楼会议室。 （三）会议召开和表决方式：采用现场表决与网络投票相结合的方式。 （四）召集人：陕西盘龙药业集团股份有限公司（以下简称"公司"）董事 会 ...

Core Insights - The company held a performance briefing for the first half of 2025, discussing key topics such as revenue growth, R&D progress, and future strategies [1][2][3] Revenue Performance - In the first half of 2025, the company's traditional Chinese medicine (TCM) decoction pieces saw a significant sales increase, achieving revenue of 123 million yuan, a year-on-year growth of 380.89%, and accounting for 21.42% of total revenue [1] - The company aims to continue expanding its TCM decoction business to enhance overall profitability [1] R&D Progress - The company reported R&D expenses of 15.85 million yuan in the first half of 2025, reflecting an 11.18% increase, outpacing the growth of over 72% in the TCM sector [2] - Multiple projects are advancing, including the TCM modified new drug PL-JT004 entering the CDE clinical acceptance stage and the chemical generic drug PL-JT001 completing BE testing [2] Digital Transformation - The company is embracing the "Internet + Medicine" trend, enhancing its digital marketing capabilities through a self-developed intelligent marketing platform, which has improved user lifecycle management efficiency by 40% and marketing response speed by 60% [3] - The company has established a professional digital marketing team and deepened strategic cooperation with major e-commerce platforms [3] Investor Engagement - The company has conducted nine investor research activities this year, indicating strong investor interest and recognition in the capital market, with the fastest revenue growth among TCM companies that have held at least nine research activities [3][4]

Core Viewpoint - The company held an online roadshow on September 10, 2025, to engage with investors regarding its traditional Chinese medicine (TCM) formula granules, innovative drug research and development, and various business segments [1] Business Growth and Strategic Layout - The company completed the construction of an intelligent production line for TCM formula granules by the end of 2024, establishing a business development center and a professional team, with 310 varieties developed and registered for market in 18 provinces, indicating the business is in its early stages and expanding from Shaanxi province [1] Innovative Drug Research and Development - In the first half of 2025, the company accelerated its innovative drug research, with the modified TCM new drug PL-JT004 entering the CDE clinical acceptance stage, and chemical generic drugs PL-JT001 completing BE testing and awaiting production reporting [2] - The company aims to cultivate major products through a gradient pipeline layout, with various innovative drugs progressing through preclinical and Phase II work [2] Business Segment Development - Revenue from TCM decoction pieces increased by 380.89% year-on-year in the first half of 2025, with its revenue share rising from 5.62% to 21.42%, although the gross margin fell by 8.46% to 3.49% [2] - The health products and daily chemicals segment saw a revenue increase of 47.49%, but its revenue share remains low at 0.14%, indicating rapid growth but small scale [2] - The chemical drug layout focuses on the fields of "rheumatism and bone diseases, chronic pain," targeting generic drugs with proven efficacy, expired patents, and significant market potential [2] Market Expansion and Management - The company employs a "professional academic promotion model" for grassroots markets, covering over 5,000 medical institutions, 30,000 retail pharmacies, and 20,000 grassroots medical units [3] - The company is enhancing its digital marketing capabilities through a self-developed intelligent marketing platform and partnerships with major e-commerce platforms [3] - Operating cash flow decreased by 43.66% year-on-year due to increased inventory procurement, while accounts receivable grew due to the low gross margin of TCM decoction pieces [3] - The company is addressing the risk of rising raw material prices by forming a procurement team and leveraging local TCM resources to establish a full industry chain [3]

Group 1: Financial Performance - The company achieved a revenue of 574.02 million yuan in the first half of 2025, representing a year-on-year increase of 118.44 million yuan, with a growth rate of 26.06% [14] - The net profit attributable to the parent company was 60.14 million yuan, showing a slight increase of 0.48 million yuan, with a growth rate of 0.81% [14] - The operating cash flow net amount decreased by 43.66% year-on-year, primarily due to increased inventory procurement payments [17] Group 2: Business Development and Strategy - The company has established a Traditional Chinese Medicine (TCM) formula granule business development center, completing the research and registration of 310 products, with approvals in 18 provinces [11] - The company is focusing on the "one body, two wings, three depths" strategy to expand its market share while enhancing profitability [3][6] - The company is actively pursuing the "Internet + medicine" strategy, enhancing digital marketing capabilities and collaborating with major e-commerce platforms [18][10] Group 3: Product and Market Insights - The revenue from TCM decoction pieces increased by 380.89% year-on-year, but the gross profit margin was only 3.49%, down 8.46% [5] - The company is addressing the low gross profit margin in the TCM decoction segment by expanding sales scale and reducing procurement costs [5][12] - The company is developing a diverse product ecosystem, including oral and external preparations, to strengthen its core competitiveness [15] Group 4: Investor Relations and Shareholder Value - The company maintains a dividend payout ratio of 17.6%, with plans to balance shareholder returns with long-term growth [4] - The company is committed to enhancing investor confidence through regular communication and transparent information disclosure [7] - The company is exploring share buybacks and other measures to stabilize market value [7] Group 5: Regulatory and Market Challenges - The company is adapting to stricter regulations in the TCM industry by enhancing compliance and quality management throughout the production process [13] - The impact of national medical insurance cost control and centralized procurement policies is being closely monitored, with strategies in place to mitigate potential effects [24] - The company is addressing the risks associated with rising prices of core raw materials by maintaining sufficient cash reserves and strategic procurement [21]

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a distribution of 1.00 yuan (including tax) for every 10 shares held by shareholders [2] - The total share capital used for the dividend calculation is 105,907,460 shares, after excluding 373,500 shares held in the repurchase account [2] - The record date for the dividend is set for September 15, 2025, and the ex-dividend date is September 16, 2025 [2]